Bladder Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Bladder Cancer > What Your Doctor is Reading About Bladder Cancer > Review Articles

Review Articles

1. Bladder cancer, a two phased disease?

Author: Hoglund M;
Institution: Department of Clinical Genetics, Lund University Hospital, Lund SE-221 81, Sweden. mattias.hoglund@med.lu.se
Journal: Semin Cancer Biol. 2007 Jun;17(3):225-32. Epub 2006 Feb 28.
Abstract URL: Click here to view abstract

2. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.

Author: Knowles MA;
Institution: Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. m.a.knowles@leeds.ac.uk
Journal: Future Oncol. 2008 Feb;4(1):71-83.
Abstract URL: Click here to view abstract

3. Biological markers in the diagnosis of recurrent bladder cancer: an overview.

Author: Mohammed A; Khan Z; Zamora I; Bhatti A;
Institution: Urology Unit, North Tees University Hospital Hardwick Road, Stockton on Tees TS19 8PE, UK. aza_bamerny@yahoo.com
Journal: Expert Rev Mol Diagn. 2008 Jan;8(1):63-72.
Abstract URL: Click here to view abstract

4. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Author: Rosenberg JE;
Institution: UCSF Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA. jrosenbe@medicine.ucsf.edu
Journal: Expert Rev Anticancer Ther. 2007 Dec;7(12):1729-36.
Abstract URL: Click here to view abstract

5. The best treatment for high-grade T1 bladder cancer is cystectomy.

Author: Skinner EC;
Institution: Department of Urology, Keck University of Southern California School of Medicine, Los Angeles, CA 90089, USA. skinner@hsc.usc.edu
Journal: Urol Oncol. 2007 Nov-Dec;25(6):523-5.
Abstract URL: Click here to view abstract

6. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Author: Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS Jr; Schellhammer PF;
Institution: American Urological Association Education and Research, Inc., USA. Craig.Hall@cornerstonehealthcare.com
Journal: J Urol. 2007 Dec;178(6):2314-30.

7. Pathological variants of invasive bladder cancer according to their suggested clinical significance.

Author: Lopez-Beltran A; Requena MJ; Cheng L; Montironi R;
Institution: Department of Pathology, Reina Sofia University Hospital and Cordoba University Medical School, Cordoba, Spain. em1lobea@uco.es
Journal: BJU Int. 2008 Feb;101(3):275-81. Epub 2007 Nov 6.
Abstract URL: Click here to view abstract

8. Surgery insight: advantages and disadvantages of laparoscopic radical cystectomy to treat invasive bladder cancer.

Author: Puppo P; Introini C; Naselli A;
Institution: Largo Rosanna Benzi 10, National Institute for Cancer Research, Genoa, Italy. paolo.puppo@auro.it
Journal: Nat Clin Pract Urol. 2007 Jul;4(7):387-94.
Abstract URL: Click here to view abstract

9. Muscle-invasive urothelial carcinoma of the bladder.

Author: Malkowicz SB; van Poppel H; Mickisch G; Pansadoro V; Thuroff J; Soloway MS; Chang S; Benson M; Fukui I;
Institution: Department of Urology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Journal: Urology. 2007 Jan;69(1 Suppl):3-16.
Abstract URL: Click here to view abstract

10. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures.

Author: Olfert SM; Felknor SA; Delclos GL;
Institution: University of Texas School of Public Health at Houston, Southwest Center for Occupational and Environmental Health, Houston, TX 77030, USA.
Journal: South Med J. 2006 Nov;99(11):1256-63.
Abstract URL: Click here to view abstract

11. Emerging drugs for targeted therapy of bladder cancer.

Author: Agarwal PK; Black PC; McConkey DJ; Dinney CP;
Institution: Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Expert Opin Emerg Drugs. 2007 Sep;12(3):435-48.
Abstract URL: Click here to view abstract

12. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.

Author: Witjes JA; Hendricksen K;
Institution: Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. F.Witjes@uro.umcn.nl
Journal: Eur Urol. 2008 Jan;53(1):45-52. Epub 2007 Aug 20.
Abstract URL: Click here to view abstract

13. Management of BCG failures in superficial bladder cancer: a review.

Author: Witjes JA;
Institution: Department of Urology, University Medical Centre St. Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands. F.Witjes@uro.umcn.nl
Journal: Eur Urol. 2006 May;49(5):790-7. Epub 2006 Jan 24.
Abstract URL: Click here to view abstract

14. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.

Author: Sylvester RJ; Oosterlinck W; Witjes JA;
Institution: EORTC Data Center, Brussels, Belgium. richard.sylvester@eortc.be <richard.sylvester@eortc.be>
Journal: Eur Urol. 2008 Apr;53(4):709-19. Epub 2008 Jan 15.
Abstract URL: Click here to view abstract

15. Quality-of-life assessment in patients with bladder cancer.

Author: Wright JL; Porter MP;
Institution: Department of Urology, University of Washington, Seattle, WA 98108, USA.
Journal: Nat Clin Pract Urol. 2007 Mar;4(3):147-54.
Abstract URL: Click here to view abstract

16. Radical cystectomy with an extended pelvic lymphadenectomy: rationale and results.

Author: Mills RD; Fleischmann A; Studer UE;
Institution: The Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK.
Journal: Surg Oncol Clin N Am. 2007 Jan;16(1):233-45.
Abstract URL: Click here to view abstract

17. Nonurothelial cancer of the bladder.

Author: Abol-Enein H; Kava BR; Carmack AJ;
Institution: Department of Urology, University of Mansoura, Urology and Nephrology Center, Egypt. hassan_abolenein@hotmail.com
Journal: Urology. 2007 Jan;69(1 Suppl):93-104.
Abstract URL: Click here to view abstract

18. Complications of intravesical therapy for urothelial cancer of the bladder.

Author: Koya MP; Simon MA; Soloway MS;
Institution: Department of Urology, University of Miami School of Medicine, Miami, Florida 33136, USA.
Journal: J Urol. 2006 Jun;175(6):2004-10.
Abstract URL: Click here to view abstract

19. Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer.

Author: Nagele U; Anastasiadis AG; Merseburger AS; Sievert KD; Stenzl A; Kuczyk M;
Institution: Department of Urology, University of Tuebingen, Hoppe-Seyler-Str. 3, Tuebingen 72076, Germany. udo.nagele@med.uni-tuebingen.de
Journal: Expert Rev Anticancer Ther. 2006 Jun;6(6):871-6.
Abstract URL: Click here to view abstract

20. Chemoprevention for bladder cancer.

Author: Busby JE; Kamat AM;
Institution: Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
Journal: J Urol. 2006 Nov;176(5):1914-20.
Abstract URL: Click here to view abstract

21. Chemotherapy practices and perspectives in invasive bladder cancer.

Author: Flechon A; Droz JP;
Institution: Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France. flechon@lyon.fnclcc.fr
Journal: Expert Rev Anticancer Ther. 2006 Oct;6(10):1473-82.
Abstract URL: Click here to view abstract

22. Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.

Author: Kausch I; Doehn C; Jocham D;
Institution: Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany. ingo.kausch@uk-sh.de
Journal: Expert Rev Anticancer Ther. 2006 Sep;6(9):1301-11.
Abstract URL: Click here to view abstract

23. The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer.

Author: Sanderson KM; Skinner D; Stein JP;
Institution: Department of Urology, at the University of Southern California, Keck School of Medicine, Los Angeles, CA 90089, USA. sanderson.km@gmail.com
Journal: Nat Clin Pract Urol. 2006 Sep;3(9):485-94.
Abstract URL: Click here to view abstract

24. Use of selenium in chemoprevention of bladder cancer.

Author: Brinkman M; Buntinx F; Muls E; Zeegers MP;
Institution: Department of General Practice, Katholieke University of Leuven, Leuven, Belgium.
Journal: Lancet Oncol. 2006 Sep;7(9):766-74.
Abstract URL: Click here to view abstract

25. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.

Author: Pectasides D; Pectasides M; Economopoulos T;
Institution: Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, 15342 Athens, Greece. pectasid@otenet.gr
Journal: Cancer Treat Rev. 2006 Oct;32(6):456-70. Epub 2006 Aug 28.
Abstract URL: Click here to view abstract

26. Bladder cancer update. Current evaluation methods and standard of care.

Author: Sonpavde G; Sonpavde G;
Institution: Texas Oncology, PA, Deke Slayton Cancer Center, Webster 77598, USA. guru.sonpavde@usoncology.com
Journal: Postgrad Med. 2006 Sep-Oct;119(3):30-7.
Abstract URL: Click here to view abstract

27. Therapy of invasive bladder cancer.

Author: Dinney CP;
Institution: Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. cdinney@mdanderson.org
Journal: Urology. 2006 Mar;67(3 Suppl 1):56-9; discussion 60-1.
Abstract URL: Click here to view abstract

28. The management of superficial transitional cell carcinoma of the bladder.

Author: Sengupta S; Blute ML;
Institution: Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Journal: Urology. 2006 Mar;67(3 Suppl 1):48-54; discussion 54-5.
Abstract URL: Click here to view abstract

29. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.

Author: Amiel GE; Lerner SP;
Institution: Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA. gamiel@bcm.tmc.edu
Journal: Expert Rev Anticancer Ther. 2006 Feb;6(2):281-91.
Abstract URL: Click here to view abstract

30. Radical radiotherapy for urinary bladder cancer: treatment outcomes.

Author: Fokdal L; Hoyer M; von der Maase H;
Institution: Department of Oncology, Aarhus University Hospital, DK-8000 C Aarhus, Denmark.
Journal: Expert Rev Anticancer Ther. 2006 Feb;6(2):269-79.
Abstract URL: Click here to view abstract

31. Benefits of laparoscopic prostate-sparing radical cystectomy.

Author: Rozet F; Harmon J; Arroyo C; Cathelineau X; Barret E; Vallancien G;
Institution: Department of Urology, Institut Montsouris, Universite Rene Descartes, 75674 Paris cedex, France. francois.rozet@imm.fr
Journal: Expert Rev Anticancer Ther. 2006 Jan;6(1):21-6.
Abstract URL: Click here to view abstract

32. Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature.

Author: Fradet Y; Aprikian A; Dranitsaris G; Siemens R; Tsihlias J; Fleshner N;
Institution: Laval University, CHUQ - Hotel-Dieu de Quebec City, Quebec, Canada.
Journal: Can J Urol. 2006 Jun;13 Suppl 3:37-47.
Abstract URL: Click here to view abstract

33. Nonplatinum therapy in advanced bladder cancer.

Author: Srinivas S; Colocci N;
Institution: Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. sandysri@stanford.edu
Journal: Expert Rev Anticancer Ther. 2006 Jun;6(6):887-94.
Abstract URL: Click here to view abstract

34. Systemic chemotherapy options for metastatic bladder cancer.

Author: Siefker-Radtke A;
Institution: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1374, Houston, TX 77030-3721, USA. asiefker@mdanderson.org
Journal: Expert Rev Anticancer Ther. 2006 Jun;6(6):877-85.
Abstract URL: Click here to view abstract

35. Radiotherapy for bladder cancer.

Author: Milosevic M; Gospodarowicz M; Zietman A; Abbas F; Haustermans K; Moonen L; Rodel C; Schoenberg M; Shipley W;
Institution: Radiation Medicine Program, Princess Margaret Hospital, and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. mike.milosevic@rmp.uhn.on.ca
Journal: Urology. 2007 Jan;69(1 Suppl):80-92.
Abstract URL: Click here to view abstract

36. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Author: Sternberg CN; Donat SM; Bellmunt J; Millikan RE; Stadler W; De Mulder P; Sherif A; von der Maase H; Tsukamoto T; Soloway MS;
Institution: Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy. cstern@mclink.it
Journal: Urology. 2007 Jan;69(1 Suppl):62-79.
Abstract URL: Click here to view abstract

37. Urinary diversion.

Author: Hautmann RE; Abol-Enein H; Hafez K; Haro I; Mansson W; Mills RD; Montie JD; Sagalowsky AI; Stein JP; Stenzl A; Studer UE; Volkmer BG;
Institution: Department of Urology, Faculty of Medicine, University of Ulm, Ulm, Germany. richard.hautmann@uniklinik-ulm.de
Journal: Urology. 2007 Jan;69(1 Suppl):17-49.
Abstract URL: Click here to view abstract

38. Systemic chemotherapy for advanced bladder cancer: update and controversies.

Author: Garcia JA; Dreicer R;
Institution: Department of Solid Tumor Oncology, Glickman Urologic Institute, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA. garciaj4@ccf.org
Journal: J Clin Oncol. 2006 Dec 10;24(35):5545-51.
Abstract URL: Click here to view abstract

39. Trimodality treatment and selective organ preservation for bladder cancer.

Author: Rodel C; Weiss C; Sauer R;
Institution: Department of Radiation Therapy, University of Erlangen, Erlangen, Germany. claus.roedel@strahlen.med.uni-erlangen.de
Journal: J Clin Oncol. 2006 Dec 10;24(35):5536-44.
Abstract URL: Click here to view abstract

40. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

Author: Parekh DJ; Bochner BH; Dalbagni G;
Institution: Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Journal: J Clin Oncol. 2006 Dec 10;24(35):5519-27.
Abstract URL: Click here to view abstract

41. Bladder cancer.

Author: Barocas DA; Clark PE;
Institution: Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2765, USA.
Journal: Curr Opin Oncol. 2008 May;20(3):307-14.
Abstract URL: Click here to view abstract

42. Neoadjuvant chemotherapy for bladder cancer.

Author: Black PC; Brown GA; Grossman HB; Dinney CP;
Institution: Department of Urology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1373, Houston, TX 77030, USA.
Journal: World J Urol. 2006 Nov;24(5):531-42.
Abstract URL: Click here to view abstract

43. Contemporary intravesical treatment options for urothelial carcinoma of the bladder.

Author: Brassell SA; Kamat AM;
Institution: Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Journal: J Natl Compr Canc Netw. 2006 Nov;4(10):1027-36.
Abstract URL: Click here to view abstract

44. Importance of node dissection in relation to neoadjuvant and adjuvant therapy.

Author: Huang WC; Bochner BH;
Institution: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA.
Journal: J Natl Compr Canc Netw. 2006 Nov;4(10):1019-26.
Abstract URL: Click here to view abstract

45. Small-cell carcinoma of the urinary bladder: diagnosis and management.

Author: Pan CX; Zhang H; Lara PN Jr; Cheng L;
Institution: University of California at Davis, Department of Internal Medicine, Division of Hematology/Oncology, Department of Urology, 4501 X Street, Room 3016, Sacramento, CA 95817, USA. cxpan@ucdavis.edu
Journal: Expert Rev Anticancer Ther. 2006 Dec;6(12):1707-13.
Abstract URL: Click here to view abstract

46. Superficial bladder cancer: part 1. Update on etiology, classification and natural history.

Author: Josephson DY; Pasin E; Stein JP;
Institution: University of Southern California, Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles CA, USA. david.josephson@usc.edu
Journal: Expert Rev Anticancer Ther. 2006 Dec;6(12):1723-34.
Abstract URL: Click here to view abstract

47. Extrapulmonary small cell carcinoma of the bladder.

Author: Shahab N;
Institution: Department of Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO, USA. nshahab65@yahoo.com
Journal: Semin Oncol. 2007 Feb;34(1):15-21.
Abstract URL: Click here to view abstract

48. Primary small cell bladder carcinoma: a case report and review of the current literature.

Author: Zachos I; Papatsoris AG; Sountoulides P; Podimatas T; Politis P; Repanti M; Vandoros G; Chrisofos M; Deliveliotis C;
Institution: Department of Urology, "Agios Andreas" Regional Hospital, Patras, Greece.
Journal: Tumori. 2006 Nov-Dec;92(6):552-4.
Abstract URL: Click here to view abstract

49. Defining optimal therapy for muscle invasive bladder cancer.

Author: Herr HW; Dotan Z; Donat SM; Bajorin DF;
Institution: Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA. herrh@mskcc.org
Journal: J Urol. 2007 Feb;177(2):437-43.
Abstract URL: Click here to view abstract

50. Laparoscopic radical cystectomy: long-term outcomes.

Author: Berger A; Aron M;
Institution: Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Journal: Curr Opin Urol. 2008 Mar;18(2):167-72.
Abstract URL: Click here to view abstract

51. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.

Author: Shapiro O; Jones K; Wang C; Landas S; Haas GP;
Institution: Upstate Medical University, Department of Urology, Syracuse, New York 13210, USA.
Journal: Can J Urol. 2006 Dec;13(6):3317-20.
Abstract URL: Click here to view abstract